Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Catriona Yale Sells 15,485 Shares

Posted by Donna Armstrong on Nov 1st, 2024

Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) insider Catriona Yale sold 15,485 shares of the business’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $32.62, for a total transaction of $505,120.70. Following the transaction, the insider now directly owns 74,158 shares in the company, valued at approximately $2,419,033.96. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

Catriona Yale also recently made the following trade(s):

On Wednesday, October 30th, Catriona Yale sold 4,515 shares of Akero Therapeutics stock. The stock was sold at an average price of $32.53, for a total transaction of $146,872.95.
On Monday, October 14th, Catriona Yale sold 6,136 shares of Akero Therapeutics stock. The shares were sold at an average price of $30.03, for a total transaction of $184,264.08.
On Friday, September 20th, Catriona Yale sold 5,500 shares of Akero Therapeutics stock. The shares were sold at an average price of $27.65, for a total value of $152,075.00.
On Wednesday, September 18th, Catriona Yale sold 3,871 shares of Akero Therapeutics stock. The stock was sold at an average price of $27.56, for a total value of $106,684.76.
On Monday, September 16th, Catriona Yale sold 2,485 shares of Akero Therapeutics stock. The shares were sold at an average price of $27.52, for a total value of $68,387.20.
On Tuesday, September 10th, Catriona Yale sold 637 shares of Akero Therapeutics stock. The stock was sold at an average price of $26.18, for a total value of $16,676.66.
On Friday, August 23rd, Catriona Yale sold 8,851 shares of Akero Therapeutics stock. The shares were sold at an average price of $27.53, for a total transaction of $243,668.03.
On Monday, August 26th, Catriona Yale sold 5,200 shares of Akero Therapeutics stock. The stock was sold at an average price of $27.51, for a total transaction of $143,052.00.

Akero Therapeutics Stock Up 4.9 %

Akero Therapeutics stock traded up $1.50 during mid-day trading on Friday, reaching $32.33. The stock had a trading volume of 1,277,374 shares, compared to its average volume of 875,147. Akero Therapeutics, Inc. has a one year low of $12.96 and a one year high of $37.00. The company has a 50-day moving average price of $28.32 and a two-hundred day moving average price of $24.76. The company has a market capitalization of $2.24 billion, a price-to-earnings ratio of -9.48 and a beta of -0.25. The company has a debt-to-equity ratio of 0.04, a current ratio of 24.89 and a quick ratio of 24.89.

Akero Therapeutics (NASDAQ:AKRO – Get Free Report) last issued its earnings results on Friday, August 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.90) by $0.09. On average, analysts expect that Akero Therapeutics, Inc. will post -3.64 EPS for the current fiscal year.

Institutional Trading of Akero Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. grew its stake in shares of Akero Therapeutics by 2,366.0% in the first quarter. Russell Investments Group Ltd. now owns 1,233 shares of the company’s stock worth $31,000 after acquiring an additional 1,183 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in Akero Therapeutics by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company’s stock worth $71,000 after purchasing an additional 446 shares during the period. Eastern Bank bought a new stake in Akero Therapeutics in the 3rd quarter worth approximately $100,000. Headlands Technologies LLC raised its stake in Akero Therapeutics by 253.5% during the 1st quarter. Headlands Technologies LLC now owns 4,217 shares of the company’s stock valued at $107,000 after buying an additional 3,024 shares during the last quarter. Finally, Ameritas Investment Partners Inc. boosted its stake in shares of Akero Therapeutics by 20.0% in the 1st quarter. Ameritas Investment Partners Inc. now owns 6,175 shares of the company’s stock worth $156,000 after buying an additional 1,030 shares during the last quarter.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $50.00 price objective on shares of Akero Therapeutics in a report on Tuesday, September 17th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, Akero Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $43.20.

Check Out Our Latest Stock Analysis on Akero Therapeutics

About Akero Therapeutics

(Get Free Report)

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.